Hiroji Iwata mostly deals with Breast cancer, Internal medicine, Oncology, Surgery and Genome-wide association study. His Breast cancer study is concerned with the larger field of Cancer. His biological study spans a wide range of topics, including Taxane, Clinical trial, Breast disease, Tamoxifen and Goserelin.
The concepts of his Surgery study are interwoven with issues in Metastasis and Trastuzumab. His study in the field of Neratinib and Trastuzumab emtansine is also linked to topics like Conjugate. Hiroji Iwata has included themes like Genetic association and Genetic predisposition in his Genome-wide association study study.
Hiroji Iwata mainly focuses on Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer. His Breast cancer research incorporates elements of Surgical oncology, Surgery, Clinical trial and Hazard ratio. His studies in Oncology integrate themes in fields like Triple-negative breast cancer, Fulvestrant, Phases of clinical research and Gynecology.
His Cancer study incorporates themes from Cancer research and Case-control study. His work deals with themes such as Odds ratio and Genome-wide association study, Genetic association, Single-nucleotide polymorphism, which intersect with Case-control study. His studies deal with areas such as Tolerability, Capecitabine and Docetaxel as well as Metastatic breast cancer.
Hiroji Iwata focuses on Breast cancer, Internal medicine, Oncology, Cancer and Metastatic breast cancer. His Fulvestrant study in the realm of Breast cancer connects with subjects such as Standard treatment. Triple-negative breast cancer, Clinical endpoint, Chemotherapy, Trastuzumab and Hazard ratio are among the areas of Internal medicine where the researcher is concentrating his efforts.
His work carried out in the field of Oncology brings together such families of science as Pembrolizumab, Tolerability, Neutropenia and Phases of clinical research. His study in Cancer is interdisciplinary in nature, drawing from both Immunohistochemistry and Cancer research. His research integrates issues of Bevacizumab, Discontinuation, Combination therapy and Family medicine in his study of Metastatic breast cancer.
His primary areas of study are Internal medicine, Breast cancer, Oncology, Trastuzumab and Triple-negative breast cancer. His work focuses on many connections between Internal medicine and other disciplines, such as Gastroenterology, that overlap with his field of interest in Neoadjuvant therapy. His Breast cancer research is multidisciplinary, incorporating elements of Guideline, Clinical trial and Family medicine.
His Oncology research integrates issues from Pembrolizumab, Cancer, Febrile neutropenia, Neutropenia and Meta-analysis. His Trastuzumab study combines topics from a wide range of disciplines, such as Receptor, Cancer research and Interstitial lung disease. His Triple-negative breast cancer research incorporates themes from First line treatment, Atezolizumab, Paclitaxel, Novel agents and Sequential chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch.
The New England Journal of Medicine (2005)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro.
Lancet Oncology (2016)
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Kyriaki Michailidou;Per Hall;Anna Gonzalez-Neira;Maya Ghoussaini.
Nature Genetics (2013)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda;Soo-Jung Lee;Shoichiro Ohtani;Young-Hyuck Im.
The New England Journal of Medicine (2017)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi;Cristina Saura;Toshinari Yamashita;Yeon Hee Park.
The New England Journal of Medicine (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss.
Lancet Oncology (2020)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
Thomas M. Suter;Marion Procter;Dirk J. van Veldhuisen;Michael Muscholl.
Journal of Clinical Oncology (2007)
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley.
Nature Genetics (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: